Subjective effectiveness of ibogaine treatment for problematic opioid consumption: Short- and long-term outcomes and current psychological functioning
AI-extracted · unverified · confirm at source
n=88 opioid patients (Crossroads, Mexico 2012-2015). 80% reported withdrawal elimination/drastic reduction. 30% never used opioids again; 54% of abstainers sustained ≥1yr. 41% sustained abstinence ≥6mo at survey.
Sample size: 88
Contraindications: Prolonged QTc interval, History of heart disease, Pulmonary embolism, Deep vein thrombosis, Severe respiratory conditions (emphysema, COPD), Obesity, Gastrointestinal disorders (Crohn's, IBS), Chronic infectious diseases, Cerebellar dysfunction, Delirium, Organic brain disease or history of severe TBI, Epilepsy, Current pregnancy, Abnormal electrolytes, Impaired hepatic or renal function, Psychotic spectrum disorders, Bipolar I disorder, Current eating disorders, Alcohol/amphetamines/cocaine use within 1 week, Long-acting opioids (buprenorphine, methadone) within 4 weeks